Why NBE Therapeutics?
Jun 22, 2020 · Treatment: Official Title: A First-in-Human, Phase 1/2 Study of NBE-002, an Anti-ROR1 Antibody Drug Conjugate, in Patients With Advanced Solid Tumors: Actual Study Start Date : June 19, 2020: Estimated Primary Completion Date : June 2025: Estimated Study Completion Date : December 2025
What are NBE injections?
With NBE 3000, it’s possible – to achieve direct results by getting a warmer, softer and more elastic muscle in less time, so you can have a greater effect from a treatment. Apart from lymphatic drainage, this therapy is very effective muscle massage, treatment and …
What is nbe-002?
Jul 01, 2019 · Abstract. Introduction: We report on the development and preclinical validation of NBE-002, a next-generation antibody drug conjugate (ADC) for the treatment of triple-negative breast cancer (TNBC). NBE-002 consists of a humanized monoclonal antibody directed against the receptor tyrosine kinase ROR1, expressed on the surface of numerous solid cancers …
Who is NBE-Therapeutics?
Dec 10, 2020 · NBE-Therapeutics is a privately-owned Swiss biotech company based in Basel and founded in 2012 with the vision of developing next-generation immune-stimulatory antibody drug conjugate (iADC™) products. NBE-Therapeutics advances its products to clinical proof of concept with the goal of improving treatment options for cancer patients.
What is NBE-002?
This first-in-human study will evaluate the recommended dose for further clinical development, safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of NBE-002, a novel anti-ROR1 antibody-drug conjugate, in patients with advanced solid tumors.
Do women have to have a negative pregnancy test?
Both male and female patients must agree to use effective contraceptive methods. Women of child-bearing potential (WCBP) must have a negative serum pregnancy test. Patients must be willing and able to sign the informed consent form, and to adhere to the study visit schedule and other protocol requirements.
Where is NBE Therapeutics based?
About NBE-Therapeutics. NBE-Therapeutics is a privately-owned Swiss biotech company based in Basel and founded in 2012 with the vision of developing next-generation immune-stimulatory antibody drug conjugate (iADC ™) products.
What is an ADC drug?
Antibody-drug conjugates (ADC’s) are a class of drugs that consist of an antibody that specifically binds to a target on tumor cells. The antibody is also linked to a cytotoxic drug to kill these cells. If the drug was given systemically, it would cause an unacceptable level of toxicity.
Is Boehringer Ingelheim family owned?
Since its founding in 1885, Boehringer Ingelheim is independent and family-owned. We have the freedom to pursue our long-term vision, looking ahead to identify the health challenges of the future and targeting those areas of need where we can do the most good.
